Document Detail


Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
MedLine Citation:
PMID:  6160594     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Concentrations of the major monoaminergic transmitter metabolites HVA, MOPEG and 5-HIAA were determined in the cerebrospinal fluid (CSF) of untreated schizophrenic patients. Patients with aberrated concentrations of 5-HIAA and HVA in CSF had schizophrenia in their families in a frequency significantly higher than that of patients with normal concentrations. These results may indicate the existence of a subgroup of schizophrenic patients having a family disposition for the disorder and an aberrated transmission from central serotonin and dopamine neurons. In young healthy volunteers, aberrated monoamine metabolite concentrations in CSF were also related significantly to a history of psychiatric morbidity in the family. In psychotic patients treated with chlorpromazine significant correlations were obtained between therapeutic outcome on the one hand, and both biochemical effects related to central monoamine metabolism and chlorpromazine concentrations in the CSF on the other hand. Patients with chlorpromazine concentrations above 1 ng/ml in CSF or 40 ng/ml in plasma responded more favourably than patients with concentrations below those levels. The results indicate that biochemical and pharmacokinetic data may be of value for diagnostic classification and prediction of therapeutic outcome in drug-treated schizophrenic patients.
Authors:
G Sedvall
Related Documents :
8163374 - Periorbital venous vasculitis, intracranial hypertension and empty sella.
8138824 - Wilson's disease with cerebral manifestation: monitoring therapy by csf copper concentr...
15101714 - Myeloma of the central nervous system: strong association with unfavorable chromosomal ...
3595664 - Cerebrospinal fluid and serum levels of albumin, igg, iga and igm in patients with intr...
23841034 - A review article: access recirculation among end stage renal disease patients undergoin...
15889124 - Evaluation of a progressive treatment program for erectile dysfunction in patients with...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Progress in biochemical pharmacology     Volume:  16     ISSN:  0079-6085     ISO Abbreviation:  Prog Biochem Pharmacol     Publication Date:  1980  
Date Detail:
Created Date:  1981-02-26     Completed Date:  1981-02-26     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0036761     Medline TA:  Prog Biochem Pharmacol     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  133-40     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / therapeutic use*
Chlorpromazine / cerebrospinal fluid*,  therapeutic use
Glycols / cerebrospinal fluid*
Homovanillic Acid / cerebrospinal fluid*
Humans
Hydroxyindoleacetic Acid / cerebrospinal fluid*
Methoxyhydroxyphenylglycol / cerebrospinal fluid*
Phenylacetates / cerebrospinal fluid*
Psychotic Disorders / drug therapy*
Schizophrenia / cerebrospinal fluid,  drug therapy,  genetics
Grant Support
ID/Acronym/Agency:
MH 27254/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Glycols; 0/Phenylacetates; 306-08-1/Homovanillic Acid; 50-53-3/Chlorpromazine; 534-82-7/Methoxyhydroxyphenylglycol; 54-16-0/Hydroxyindoleacetic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphism of human B-cell alloantigens: evidence for three loci within the HLA system.
Next Document:  Substance P and analogues: biological activity and degradation.